ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Hepatitis B Vaccine Almost Ready, Blumberg Tells Science Writers

April 10, 1981

More Workers Quit Smoking When Health Messages Combined

August 30, 2002

House Committee Investigates ESA Safety, Urges Amgen, J&J, To Stop Promotions.

March 23, 2007

Davis Denies “Cherry-Picking” Data To Support Her Claims.

August 1, 2008

ASCO Picks University of Michigan Medical School Dean Allen Lichter As Exective Vice President and CEO.

July 14, 2006

$14.7 Million Earmark Of NCI funds Trigger Protest By Advocates, Scientists

October 24, 1996